<Edwin> The shareholders can assume that David Salmon will either 1. re-negotiate to keep what he has pre closin.

2. Get new shares as compensation post closing or 3. Get a salary plus new shares post closing. The Kearney and Mullineaux shares (8 Million) will be absorbed by the 95% side of the transaction so they have a non-dilutive effect to the 5% side.

So, technically they may not be sent to the transfer agent and canceled, but will be mathematically computed to represent there portion of the current beneficial ownership of Med Tech Labs, Inc.

<Cinswen> Question #2B Does this mean that Kearney and Mullineaux's Monogram 8 Million shares will be exchanged for 8 Million shares of Med Tech Labs, Inc. and 8 Million shares of Medical Discounts Limited, Inc. (MDL)...
and If so will they have to file a 144 form with the SEC to sell any of the Newly issued Med Tech Labs, Inc. shares?

<Edwin> It's not useful to equate number of shares between companies. Quite frankly, we won't do the exact math until right before closing. Percentages are how we think of the deal right now. Med Tech Labs, Inc. has only 5 shareholders that will own 95% of Monogram post closing. All of which will be "Restricted Securities" as defined by the SEC. Restricted for 2 years and then assuming each are still affiliates after 2 years, form 144 would be required as well as form 3's and 4 for 10% owner or more.

There is no direct relationship between the Kearney and Mullineaux shares and MDL. Again we think in percentages at this point. That group of shareholders that will represent the 5% of Monogram post closing (all shareholders except the current holders of Med Tech Stock) will own 95% of MDL.

Kearney and Mullineaux will have NO additional interest in MDL beyond that which all shareholders of Monogram have post closing. Monogram (The company) will retain 5% ownership in MDL. That will show up as an asset on Monogram's books.

<Cinswen> Question #2C What does it mean "current shareholders"? (also included in the January 30th press release:)
The current shareholders of Med Tech Labs, Inc., adjusted for the return of the Kearney, Mullineaux and Salmon shares, will own 95% of the issued and outstanding stock of Monogram Pictures, Inc. at closing. The transaction includes the distribution through a stock dividend of Medical Discounts Limited, Inc. to the same Monogram Pictures, Inc. shareholders adjusted for the Kearney, Mullineaux and Salmon tender. Each shareholder will own shares of two companies subsequent to closing subject to an effective Registrations Statement with the Securities and Exchange Commission.

<Edwin> This may be answered above, but to put it another way. The intent is to separate the private owners of Med Tech Labs, Inc. from the shareholders of Monogram and re-distribute Monogram at the ratio of 95:5.

Kearney and Mullineaux are Med Tech Labs, Inc. security holders now and will be treated as such. Since the shareholders of Monogram brought to the negotiation table a wholly owned subsidiary called MDL, we, speaking as the holders of Med Tech Labs, Inc. and future majority holders of Monogram wanted to give back MDL to the original shareholders but retain a 5% interest.

We, speaking as Monogram intend on funding MDL as investors for several reasons. MDL is complimentary to our (Lab) business and we have the funds to do so. MDL will file a registration statement so its shares may be traded on an exchange.

We can then leverage our investment banking contacts to further assist its growth.

<Cinswen> Question #3 has this been approved by the SEC and if so what filings would it be under?

<Edwin> The SEC does not "approve" acquisition transactions. They do require certain disclosure with timeline requirements. Such as Annual (10K) , quarterly (10Q) and current reports (8K).

<Cinswen> Question #4 Was A.S.K. Consulting, Inc. formed for the sole purpose of merging with Med-Tech Labs, Inc. d/b/a Med Services of America's ?

<Edwin> No, see above.

<Cinswen> Question #5 What will be the amount of Authorized shares ?

<Edwin> 100,000,000

<Cinswen> Question #6 What will be the amount of outstanding shares ?

<Edwin> It is anticipated that after the closing there will be approximately 10 million issued and outstanding. That will be accomplished by a reverse split first, then issuance to the holders of Med Tech Labs, Inc. an amount equal to 95%.

Resulting in a total of 10 million issued and outstanding. This number is subject to change based on our investment banking relationships input that may deem it necessary to have more or less out.

In any case the percentages will remain the same between the current Monogram holders and Med Tech Labs, Inc. Holders.

<Cinswen> Question #7 What % of shares will the insiders hold after the merger?

<Edwin> 95%

<Cinswen> Question #8 Will the shareholder of MOPP receive shares of Medical Discounts Limited?

<Edwin> Yes, however, the shares of MDL will likely be forward split to accommodate a public market. I believe the current issued and outstanding is 500,000 to Monogram.

<Cinswen> Question #9 Does the Company plan on taking Medical Discounts Limited, Inc. (MDL) public?
If so what time frame?

<Edwin> I believe what you are asking is "will our MDL shares be registered with the SEC so they may be traded on an exchange?" The answer is yes. However, once a registration statement is filed, most likely on Form SB-2, the SEC will usually ask for clarification on certain points.

This process can go through several rounds of comments each taking 15-45 days each. We have seen them pass with no comment on the first submittal and we have seen them go through 5 and 6 rounds. We plan on submitting a registration statement during the second quarter of 2002.

<Cinswen> Question #10 What is the anti-dilutive provision which will be effective for a period of twelve months from the date of any definitive agreement, which governs the business combination transaction between Monogram and Med-Tech Labs, Inc. d/b/a Med Services of America's ?

<Edwin> This provision protects the current Monogram holders (non Med Tech Labs, Inc.) from being reduced below 5% for issuance other than acquisitions etc. For instance, we will acquire several labs this year with stock or cash raised from stock.

The acquisition may or may not be dilutive to book value. The anti-dilutive provision would not apply in that case. On the other hand, if Monogram issues a bunch of stock for services for which it does not acquire an asset, the anti-dilutive provision would apply.

<Cinswen> Question #11 Ed Salmon mentioned as COO of stampede Worldwide.Inc for the past 5 years. In recent filings, why no mention of HITT? Was that not within the 5 yr period?

<Edwin> David Salmon (my 38 yr. old son) was COO of Stampede and served as a director for a period of time. David Salmon never had any involvement in HITT. David's disclosure was required on Form S-8.

I (Edwin B. Salmon, Jr.) am the Chairman and CEO of Med Tech Labs, Inc. and its largest shareholder. I am now the Chairman and CEO of Monogram Pictures, Inc. In an effort to bring the maximum value to shareholders of a company named Systems Communications, Inc., I completed a transaction with a California Corporation called Hitsgalore.com, Inc.

I never had any executive (or otherwise) positions with Hitsgalore. I was on the other side of the transaction.

The shareholders that benefited from the transaction remain my close supporters and most are now shareholders in Monogram through open market purchases.

My personal disclosure will be forthcoming in required SEC filings. But some highlights are. In 1993 I was Chairman of Contour Medical, Inc. The stock was listed on the OTC Bulletin Board and rose to $6.75 from $.15 over the ensuing year and a half.

We sold the company to a larger medical company at that time. Some of those shareholders are still we me today. What was once Contour Medical is now part of a Larger National Company.

I've been so busy preparing Med Tech for the public market I haven't even check their price in two years. It was around $30 then. Maybe one of you research pros could track that down for us. I don't even remember their symbol to tell you the truth.

In case you were wondering, Systems/Hitsgalore was in between Contour and Med Tech Labs, Inc. I should mention that our CFO, Thomas Kearney has a quite the experience too.

For 22 years Tom was an independent investment banker, Tom provided private companies expertise introducing them to the public equity arena.

Tom was involved with Kinder-Care, Inc., Brookwood Heath Services, HealthCare Corporation, Hospital Corporation of America (HCA), Laservision Inc. and Laser Sight, Inc. to name a few.

<Cinswen> Question #12 You sold the film library which you bought from Media Concepts. Is it true that MDCE, Mediaconcepts, Inc. has a preferred certificate for 175K shares? And that there is a lawsuit pending with a gentleman named Steve Swank, and until this is settled the merger will not go through?

<Edwin> We have been aware of that suit since the first talks with Steve Swank. Steve filed the suit as Monogram's CEO and has been very forthcoming in assisting the due diligence. We deem the suit in which we are the plaintiffs to be non material under Item 103 of Regulation SB.

No issues remain regarding the preferred stock mentioned in the Agreement Providing for the Exchange of Capital Stock that would prevent the closing of the transaction.

<Cinswen> Thank you! This is the end of all the questions members submitted before hand.

<TJ^> Thank you Mr. Salmon

<Edwin> Thank you Cindy

<TJ^> A question from Carlos - You mentioned a forward split - what ratio and what timeframe....thanks.

<Edwin> That has not been fully determinded as yet. However, with only 500,000 shares issued. It would seem that at least a 4:1 would be reasonable. Upon registration statement submittal for MDL refer to #8 above.

<Cinswen>Question from dooley - how are they going to handle the payment of the preferred stock and what are the terms on the preferred stock? Thank you.

<Edwin> Although we deemed it non-material, see #12 above. It is however, ongoing and we can't comment on the further.
We are aware that this topic is of interest to the shareholders at large. We will provide a public statement as soon as possible.

<Cinswen> What's the time line? Can you say?

<Edwin> We are still confirming our guidance for a March 30th closing.

<Cinswen> Thank you.

<TJ^> Thank you Mr Salmon -That concludes all questions we have received.

<Cinswen> Mr. Salmon, you have been very helpful.

<Edwin> Thank you Cindy, I would like to add that Robert Parker has obtained a verbal agreement on a National Distribution contract for MDL's subscription card. We will file this statement on Form 8K in the morning, hopefully it will include confirmation and the signed deal with fuller disclosure on the terms.

<Cinswen> Thank you all for joining us. And thank you once again Mr. Salmon.

<Edwin> Thank you all for attending, please feel free to contact our Investor Realtions Department - Edwin.